Xenon MRI advances as a key cardiopulmonary biomarker at ATS 2026, boosting lung disease research and drug trials.

Polarean showcased its Xenon MRI technology at the ATS 2026 Respiratory Innovation Summit and International Conference, highlighting its role as a noninvasive biomarker platform for cardiopulmonary diseases. The technology enables detailed lung function imaging, aiding clinical trials and treatment assessment, especially in pediatric and early-life lung diseases. With over 20 presentations, Xenon MRI is gaining momentum for monitoring lung physiology and drug development, offering new insights beyond traditional methods. Polarean's FDA-approved XENOVIEW contrast agent supports safer, radiation-free lung imaging, addressing global respiratory health challenges.